

Listing of the Linking Claims

1. **(Original)** A pharmaceutical composition for the treatment of gastrointestinal disorders comprising:
 - a. one or more antifatulent;
 - b. one or more competitive reversible histamine H₁-receptor antagonist; and
 - c. a pharmaceutically acceptable carrier.
2. **(Original)** The pharmaceutical composition of claim 1 further comprising one or more probiotic.
3. **(Original)** The pharmaceutical composition of claim 1 further comprising one or more probiotic.
4. **(Original)** The pharmaceutical composition of claim 1, wherein the gastrointestinal disorder is selected from the group consisting of acid indigestion, colic, diarrhea, heartburn, irritable bowel syndrome, sour stomach, gas associated with the foregoing conditions, peptic ulcer disease of the esophagus, stomach or duodenum, indigestion, flatulence, dyspepsia of unknown origin including cancer of the stomach, infiltrative disease of the stomach including lymphoma, Crohn's disease, eosinophilic granuloma, tuberculosis, syphilis and sarcoidosis, abdominal lesions, chronic pancreatitis, biliary disease, Zollinger-Ellison syndrome, motion sickness, and otitis media.
5. **(Original)** A method for the treatment of gastrointestinal disorders comprising administering to a subject in need thereof, a therapeutically effective dose of the composition of claim 1.
6. **(Original)** The method of claim 5 wherein the gastrointestinal disorders are selected from the group consisting of acid indigestion, colic, diarrhea, heartburn, irritable bowel syndrome, sour stomach, gas associated with the foregoing conditions, peptic ulcer disease of the esophagus, stomach or duodenum, indigestion, flatulence, dyspepsia of unknown origin including cancer of the stomach, infiltrative disease of the stomach including lymphoma, Crohn's disease,

eosinophilic granuloma, tuberculosis, syphilis and sarcoidosis, abdominal lesions, chronic pancreatitis, biliary disease, Zollinger-Ellison syndrome, motion sickness, and otitis media.

7. **(Original)** A pharmaceutical composition for the treatment of colic comprising:
 - a. one or more antifatulent;
 - b. one or more competitive histamine H₁-receptor antagonist; and
 - c. a pharmaceutically acceptable carrier.
8. **(Original)** The pharmaceutical composition of claim 7, wherein the antifatulent is selected from the group consisting of maltodextrin and organopolysiloxanes.
9. **(Original)** The pharmaceutical composition of claim 8, wherein the antifatulent is an organopolysiloxane selected from the group consisting of dimethicone, dimethylpolysiloxane, methylpolysiloxane and simethicone.
10. **(Original)** The pharmaceutical composition of claim 9, wherein the organopolysiloxane is simethicone.
11. **(Original)** The pharmaceutical composition of claim 10, wherein the simethicone is present in an amount from about 40 mg/ml to about 120 mg/ml.
12. **(Original)** The pharmaceutical composition of claim 11, wherein the simethicone is present in an amount of about 80 mg/ml.
13. **(Original)** The pharmaceutical composition of claim 7, wherein the histamine H₁-receptor antagonist is selected from the group consisting of acrivastine, astemizole, azatadine, azclastine, bromodiphenhydramine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyproheptadine, desloratadine, dexbrompheniramine, dexchlorpheniramine, diphenhydramine, doxylamine, fexofenadine, hydroxyzine, ketotifen, loratadine, norastemizole, phenindamine, pyrilamine, temelastine, terfenadine, tripeleminamine and triprolidine.

14. **(Original)** The pharmaceutical composition of claim 13, wherein the histamine H₁-receptor antagonist is diphenhydramine.
15. **(Original)** The pharmaceutical composition of claim 14, wherein the diphenhydramine is present in an amount from about 1.0 mg/ml to about 4.0 mg/ml.
16. **(Original)** The pharmaceutical composition of claim 15, wherein the diphenhydramine is present in an amount of about 2.0 mg/ml.
17. **(Original)** The pharmaceutical composition of claim 7 further comprising one or more prebiotic.
18. **(Original)** The pharmaceutical composition of claim 17 wherein the prebiotic is selected from the group consisting of larch arabinogalactans, lactulose, lactitol, oligosaccharides and inulin.
19. **(Original)** The pharmaceutical composition of claim 18 wherein the prebiotic is larch arabinogalactans.
20. **(Original)** The pharmaceutical composition of claim 19, wherein the larch arabinogalactans are present in an amount from about 25 mg/ml to about 500 mg/ml.
21. **(Original)** The pharmaceutical composition of claim 20, wherein the larch arabinogalactans are present in an amount of about 250 mg/ml.
22. **(Original)** The pharmaceutical composition of claim 7 further comprising one or more probiotic selected from the group consisting of *Bifidobacterium species* such as *Bifidobacterium bifidum*, *Bifidobacterium brevis*, *Bifidobacterium longus*, *Bifidobacterium infantis*; *Lactobacillus species*, such as, *Lactobacillus acidophilus*, *Lactobacillus bifidus*, *Lactobacillus brevis*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus delbruekii*, *Lactobacillus lactis*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*,

Lactobacillus salivarius; Enterococcus faecium; Saccharomyces boulardii; and Streptococcus thermophilus.

23. **(Original)** The pharmaceutical composition of claim 7, wherein the composition is substantially free of dyes, alcohols, artificial flavors, artificial sweeteners and artificial preservatives.

24. **(Original)** The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is in a liquid dosage form.

25. **(Original)** The pharmaceutical composition of claim 24, wherein the liquid dosage form is a suspension.

26. **(Original)** The pharmaceutical composition of claim 7, wherein the composition is in a solid dosage form.

27. **(Original)** A method for the treatment of colic comprising administering to a subject in need thereof one or more antifatulent and one or more competitive histamine H₁-receptor antagonist.

28. **(Original)** The method according to claim 27, wherein the antifatulent is selected from the group consisting of maltodextrin and organopolysiloxanes.

29. **(Original)** The method according to claim 28, wherein the antifatulent is an organopolysiloxane selected from the group consisting of, dimethicone, dimethylpolysiloxane, methylpolysiloxane and simethicone.

30. **(Original)** The method according to claim 29, wherein the organopolysiloxane is simethicone.

31. **(Original)** The method according to claim 30, wherein the simethicone is administered three (3) to six (6) times daily in an amount from about 25 mg/0.6ml to about 50 mg/0.6ml.
32. **(Original)** The method according to claim 31, wherein the simethicone is administered four times daily in an amount of about 40mg/0.6ml.
33. **(Original)** The method according to claim 27, wherein the histamine H₁-receptor antagonist is selected from the group consisting of acrivastine, astemizole, azatadine, azclastine, bromodiphenhydramine, brompheniramine, cetirizine, chlorpheniramine, clematine, cyproheptadine, desloratadine, dexbrompheniramine, dexchlorpheniramine, diphehydramine, doxylamine, fexofenadine, hydroxyzine, ketoffen, loratidine, norastemizole, phenindamine, pyrilamine, temelastine, terfenadine, tripeleminamine and triprolidine.
34. **(Original)** The method according to claim 33, wherein the histamine H₁-receptor antagonist is diphenhydramine.
35. **(Original)** The method according to claim 34, wherein the diphenhydramine is administered three (3) to six (6) times daily in an amount from about 0.50 mg/0.6ml to about 2.0 mg/0.6ml.
36. **(Original)** The method according to claim 35, wherein the diphenhydramine is administered four (4) times daily in an amount of about 1.25mg/0.6ml.
37. **(Original)** The method according to claim 27 further comprising administering one or more prebiotic selected from the group consisting of larch arabinogalactans, lactulose, lactitol, oligosaccharides and inulin.
38. **(Original)** The method according to claim 37 wherein the prebiotic is larch arabinogalactans.

39. **(Original)** The method according to claim 38, wherein the larch arabinogalactans is administered three (3) to six (6) times daily in an amount of about 100mg/0.6ml to about 250mg/0.6ml.

40. **(Original)** The method according to claim 39, wherein the larch arabinogalactans is administered four times daily in an amount of about 125mg/0.6ml.

41. **(Original)** The method according to claim 27 further comprising administering one or more probiotic selected from the group consisting of *Bifidobacterium species* such as *Bifidobacterium bifidum*, *Bifidobacterium brevis*, *Bifidobacterium longus*, *Bifidobacterium infantis*; *Lactobacillus species*, such as, *Lactobacillus acidophilus*, *Lactobacillus bifidus*, *Lactobacillus brevis*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus delbruekii*, *Lactobacillus lactis*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus salivarius*; *Enterococcus faecium*; *Saccharomyces boulardii*; and *Streptococcus thermophilus*.